Lavipharm

Lavipharm EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Lavipharm (LAVI.AT) as of Nov 4, 2026 is 33.34. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 56.07 — a change of -40.54% (lower).

EV/EBIT

33.34

YoY

-40.54%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Lavipharm is 2025 33.34 . EV/EBIT (Enterprise Value to EBIT) of Lavipharm was 2024 56.07 . It decreases by -40.54% lower compared to the previous year.

The Lavipharm EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2019
272.48 EUR
Jan 1, 2020
121.90 EUR
Jan 1, 2021
-599.72 EUR
Jan 1, 2022
88.73 EUR
Jan 1, 2023
57.09 EUR
Jan 1, 2024
56.07 EUR
Jan 1, 2025
33.34 EUR
Jan 1, 2026 (e)
21.21 EUR
The Lavipharm EV/EBIT history
YEAREV/EBITYoY
est21.21-36.38%
33.34-40.54%
56.07-1.79%
57.09-35.66%
88.73-114.80%
-599.72-591.96%
121.90-55.26%
272.48-142.24%
-645.11-421.35%
200.75-321.03%
-90.83-31.35%
-132.31+608.88%
-18.66+363.15%
-4.03-71.76%
-14.27+29.96%
-10.98-209.15%
10.06-101.38%
-727.74+4,932.78%
-14.46-120.04%
72.15+44.56%
49.91—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lavipharm Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Lavipharm's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Lavipharm's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Lavipharm's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Lavipharm grows earnings faster than its peers.

Lavipharm Stock analysis

What does Lavipharm do? Lavipharm SA manufactures and imports pharmaceuticals and veterinary products, with main categories including anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological, and gastrointestinal therapies. The company offers cosmetic products under the brands Castalia Soins Dermocosmetiques and Laviderm Active Technology for skin, face, body, scalp, and hair care. Its OTC products encompass cold and flu remedies, oral care, dermatological items, condoms, antiseptics, analgesics, laxatives, and gynecology products. The company is the parent of Lavipharm Group of Companies and previously sold HITEX, a carbon dioxide extraction subcontracting business, to Robertet SA and CODIF in January 2014. Lavipharm SA's revenue streams come from the sale of pharmaceuticals, veterinary products, cosmetics under Castalia and Laviderm, and OTC products. Pharmaceutical and veterinary products target healthcare providers and pharmacies, while cosmetics and OTC products are sold directly to consumers through retail channels. The company's brand portfolio includes Castalia Soins Dermocosmetiques, Laviderm Active Technology, and its core pharmaceutical lines, with segments defined by product categories and distribution channels. The company's primary customers are healthcare professionals and retail consumers, with pharmaceuticals distributed via pharmacies and veterinary products to animal care facilities. Cosmetic products under Castalia and Laviderm are sold to consumers for personal care, and OTC products reach consumers through general retail. The sale of HITEX to Robertet SA and CODIF in 2014 was a one-time transaction that contributed to the company's financials during that period. Lavipharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lavipharm stock

EV/EBIT (Enterprise Value to EBIT) of Lavipharm is 33.34 in 2025.

EV/EBIT (Enterprise Value to EBIT) of Lavipharm changed from 56.07 to 33.34, representing a -40.54% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Lavipharm since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Lavipharm with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Lavipharm

All Key Metrics — Lavipharm